Search results
Milwaukee police pursuit, driver arrested; drugs, 'ghost gun' found
WITI via Yahoo News· 3 days agoSeveral bags were also recovered. One bag had multicolored and multi-shaped pills suspected to be...
Precigen Reports First Quarter 2024 Financial Results and Business Updates
Morningstar· 7 days ago– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation on June 3rd – – Company to host a conference
Earnings call: Belite Bio highlights progress in key drug trials, Q1 financials By Investing.com
Investing.com· 6 days agoDespite reporting increased research and development expenses and a net loss for the quarter, Belite...
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results
Morningstar· 5 days agoEnrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025Company committed to addressing the most aggressive type of brain cancer ...
Salzburg Intensive Care database (SICdb): a detailed exploration and comparative analysis with...
Nature· 1 day agoThe data in the SICdb have been anonymized in accordance with article 4(5) of the European General Data Protection Regulation (GDPR) 28. The database includes data exclusively from ICU patients ...
Washington County Grand Jury
The Marietta Times· 5 days agoThe Washington County Grand Jury indicted 24 people this week on a variety of charges. The following indictments were issued: * Marcus Evan MacAuley, 18, Marietta, third-degree strangulation ...
Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose...
Morningstar· 7 days agoALACHUA, Fla. and CHICAGO, May 14, 2024 /PRNewswire/ -- Nanopharmaceutics, Inc. (OTC:TGRP), a clinical-stage pharmaceutical development company, announced the initiation of a Phase I clinical study with the Robert H. Lurie Comprehensive Cancer Center
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 5 days agoAvenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 6 days agoPreliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell
Carisma Therapeutics begins trial for novel cancer therapy By Investing.com
Investing.com· 5 days agoCarisma Therapeutics Inc. (NASDAQ: CARM), a biopharmaceutical company, announced today the...